Found 930 All Conditions trials
A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
The Investigation Device Exemption (IDE) study will evaluate the safety of delivering Aliya PEF in patients with metastatic cancer within the lungs or stage IV non-small cell lung cancer NSCLC) who are treatment-naïve and indicated for first-line standard of care (SOC) cancer therapy.
Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) is also known as LGMD R9 FKRP-related and is therefore referred to as LGMD2I/R9 . This study will evaluate the safety and efficacy of long-term administration of BBP-418 in patients with LGMD2I/R9. The study will include patients ages 12 to 60, consistent with the …
Please refer to Protocol PRT3645-01, Section 5 (Objectives, Endpoints, and Estimands) Please refer to Protocol PRT3645-01, Section 5 (Objectives, Endpoints, and Estimands) Please refer to Protocol PRT3645-01, Section 5 (Objectives, Endpoints, and Estimands)
Please refer to the protocol, Section 2 (Objectives and Endpoints) Please refer to the protocol, Section 2 (Objectives and Endpoints) Please refer to the protocol, Section 2 (Objectives and Endpoints)
This is a screening study to test patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol.
Please refer to the protocol, section 2.2 (Objectives and Endpoints) Please refer to the protocol, section 2.2 (Objectives and Endpoints) Please refer to the protocol, section 2.2 (Objectives and Endpoints)
This is a Phase Ib/II study in participants with advanced liver cancers. Cohort 1 - participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy for their disease. Participants who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible …
See Section 3: Study Objectives and Endpoints of the attached protocol. See Section 3: Study Objectives and Endpoints of the attached protocol. See Section 3: Study Objectives and Endpoints of the attached protocol.
This study is a randomized, open label, multicenter Phase II trial to evaluate the efficacy and safety of botensilimab (a novel Fc enhanced Tree depleting anti-CTLA4) and balstilimab (a novel anti-PD1) relative to ipilimumab and nivolumab in treatment naïve patients with metastatic ccRCC. We would like to rely on WCG …
